^
    CANCER:

    Neuroendocrine Tumor





    Show legend
    Group by Gene:
    Include preclinical:

    0
    DNA synthesis inhibitor
    temozolomide
    dacarbazine
    1
    mTOR inhibitor
    everolimus
    2
    Thymidylate synthase inhibitor
    5-fluorouracil
    capecitabine
    pembrolizumab
    		3
    PD1 inhibitor
    toripalimab-tpzi
    PDR001
    4
    PD1 inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab
    5
    DNA synthesis inhibitor, Thymidylate synthase inhibitor
    temozolomide + capecitabine
    6
    SSTR agonist
    lanreotide prolonged-release subcutaneous
    7
    Tubulin polymerization promoter, Topoisomerase I inhibitor
    carboplatin + irinotecan
    8
    DNA synthesis inhibitor, DNA cross linking agent
    oxaliplatin
    9
    DNA synthesis inhibitor, Topoisomerase I inhibitor
    cisplatin + irinotecan
    10
    Tubulin polymerization promoter, Microtubule inhibitor
    carboplatin + cabazitaxel
    11
    VEGFR inhibitor, FGFR1 inhibitor
    surufatinib
    12
    ALK inhibitor
    alectinib
    crizotinib
    13
    TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
    larotrectinib
    14
    RET inhibitor
    selpercatinib
    pralsetinib
    15
    Multi-tyrosine kinase inhibitor
    pazopanib
    16
    HIF-2α antagonist
    MK-3795
    17
    HIF-2α inhibitor
    belzutifan
    18
    Estrogen receptor antagonist
    tamoxifen
    19
    Ionizing radiation emitter, SSTR2 inhibitor
    lutetium Lu 177 dotatate
    20
    MEK inhibitor, BRAF inhibitor, BRAF V600E inhibitor
    trametinib + vemurafenib
    21
    Tubulin polymerization inhibitor, SSTR2 inhibitor
    PEN-221
    22
    VEGFR inhibitor, FGFR1 inhibitor, PD1 inhibitor
    toripalimab-tpzi + surufatinib
    23
    MEK inhibitor, BRAF inhibitor
    trametinib + dabrafenib
    24
    ALK inhibitor, Multi-tyrosine kinase inhibitor
    crizotinib + pazopanib
    25
    BRAF inhibitor, EGFR inhibitor
    EGFR inhibitor + BRAF inhibitor
    EP
    FOLFOX
    FOLFIRINOX
    FOLFIRI
    		26
    Chemotherapy
    CAPOX
    FAS
    CAPTEM
    CVD
    TC
    mFOLFOX6
    27
    Immunotherapy
    Immunotherapy
    28
    VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor
    sunitinib
    29
    Topoisomerase II inhibitor, DNA synthesis inhibitor
    cisplatin + etoposide IV
    30
    Topoisomerase II inhibitor, Tubulin polymerization promoter
    carboplatin + etoposide IV
    31
    DLL3 inhibitor, CD3 agonist
    BI 764532
    32
    TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor inhibitor, ALK inhibitor, JAK2 inhibitor, TNK2 inhibitor
    entrectinib
    33
    DLL3-targeted antibody-drug conjugate, DNA replication inhibitor
    rovalpituzumab tesirine
    34
    SSTR2 inhibitor, α radiation emission
    RYZ101
    ORM-2110
    35
    cRAF inhibitor, BRAF inhibitor, EGFR inhibitor
    cetuximab + encorafenib
    36
    ROS1 inhibitor, ALK inhibitor
    lorlatinib
    37
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, c-KIT inhibitor, PDGFR α antagonist
    lenvatinib
    38
    Topoisomerase II inhibitor
    doxorubicin hydrochloride
    39
    VEGFR inhibitor, PDGFR inhibitor, ALK inhibitor, c-KIT inhibitor
    crizotinib + sunitinib
    40
    PARP inhibitor
    olaparib
    41
    CEACAM5-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    IMMU-130
    No biomarker
    SSTR positive
    PD-L1 expression
    SSTR Expression
    MSI-H/dMMR + PD-L1 expression
    PD-L1 elevation
    BRAF V600E
    DLL3 overexpression
    MGMT underexpression
    MGMT deletion
    DLL3 positive
    MGMT promoter methylation
    DLL3 expression
    NTRK3 fusion
    RET fusion
    VHL mutation
    TMB-L
    ALK positive
    ALK rearrangement
    TMB-H
    SDHB mutation + SDHD mutation
    NTRK1 fusion
    KIF5B-RET fusion
    SSTR2 positive
    mTOR expression + RPS6KB1 expression
    TP53 mutation
    ARID1A mutation
    HRAS overexpression
    MEN1 mutation + DAXX wild-type
    ER positive + PGR positive
    NTRK2 fusion
    EWSR1-CREB1 fusion
    MUC16 elevation
    TMB-L + PD-L1 expression
    ETV6-NTRK3 fusion
    EML4-ALK fusion
    MSI-H/dMMR
    SSTR2 underexpression
    FLT4 T494A
    CA9 overexpression
    TYRO3 mutation + ALK mutation
    FGFR4 G388R
    TGFB1 elevation
    BRCA2 exon 11 deletion
    CEACAM5 expression
    FLT4 R1324L